M. Vermeer
Medisch Spectrum Twente
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Vermeer.
Arthritis & Rheumatism | 2011
M. Vermeer; Hillechiena H. Kuper; M. Hoekstra; Cees J. Haagsma; Marcel D. Posthumus; Herman L. M. Brus; Piet L. C. M. van Riel; Mart A F J van de Laar
OBJECTIVE Clinical remission is the ultimate therapeutic goal in rheumatoid arthritis (RA). Although clinical trials have proven this to be a realistic goal, the concept of targeting at remission has not yet been implemented. The objective of this study was to develop, implement, and evaluate a treat-to-target strategy aimed at achieving remission in very early RA in daily clinical practice. METHODS Five hundred thirty-four patients with a clinical diagnosis of very early RA were included in the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Treatment adjustments were based on the Disease Activity Score in 28 joints (DAS28), aiming at a DAS28 of <2.6 (methotrexate, followed by the addition of sulfasalazine, and exchange of sulfasalazine with biologic agents in case of persistent disease activity). The primary outcome was disease activity after 6 months and 12 months of followup, according to the DAS28, the European League Against Rheumatism (EULAR) response criteria, and the modified American College of Rheumatology (ACR) remission criteria. Secondary outcomes were time to first DAS28 remission and outcome of radiography. RESULTS Six-month and 12-month followup data were available for 491 and 389 patients, respectively. At 6 months, 47.0% of patients achieved DAS28 remission, 57.6% had a good EULAR response, and 32.0% satisfied the ACR remission criteria. At 12 months, 58.1% of patients achieved DAS28 remission, 67.9% had a good EULAR response, and 46.4% achieved ACR remission. The median time to first remission was 25.3 weeks (interquartile range 13.0-52.0). The majority of patients did not have clinically relevant radiographic progression after 1 year. CONCLUSION The successful implementation of this treat-to-target strategy aiming at remission demonstrated that achieving remission in daily clinical practice is a realistic goal.
Annals of the Rheumatic Diseases | 2012
M. Vermeer; H.H. Kuper; Arie E. van der Bijl; H. Baan; M.D. Posthumus; H.L.M. Brus; P.L.C.M. van Riel; Mart A F J van de Laar
Rheumatology | 2010
M. Vermeer; H.H. Kuper; M. Hoekstra; H.J. Bernelot Moens; M.D. Posthumus; H.L.M. Brus; P.L.C.M. van Riel; Mart A F J van de Laar
EULAR 2010, Annual European Congress of Rheumatology | 2010
M. Vermeer; H.H. Kuper; M. Hoekstra; H.J. Bernelot Moens; P.L.C.M. van Riel; Mart A F J van de Laar
Arthritis & Rheumatism | 2010
M. Vermeer; H.H. Kuper; M. Hoekstra; H.J. Bernelot Moens; P.L.C.M. van Riel; Mart A F J van de Laar
Annals of the Rheumatic Diseases | 2016
M. Vermeer; A. ter Avest; H.J. Bernelot Moens
Archive | 2012
M. Vermeer; H.H. Kuper; H.J. Bernelot Moens; M. Hoekstra; Posthumus; P.L.C.M. van Riel; Mart A F J van de Laar
Archive | 2012
M. Vermeer; Ina H. Kuper; Hein J. Bernelot Moens; M. Hoekstra; Marcel D. Posthumus; P.L.C.M. van Riel; Mart A F J van de Laar
Archive | 2012
M. Vermeer; Wietske Kievit; Ina H. Kuper; Louise Marie Antoinette Braakman-Jansen; Hein J. Bernelot Moens; T.R. Zijlstra; Alfons A. den Broeder; P.L.C.M. van Riel; Jaap Fransen; Mart A F J van de Laar
Archive | 2012
M. Vermeer; Wietske Kievit; Ina H. Kuper; Louise Marie Antoinette Braakman-Jansen; H.J. Bernelot Moens; T.R. Zijlstra; A.A. den Broeder; P.L.C.M. van Riel; Mart A F J van de Laar